JP2014534233A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014534233A5 JP2014534233A5 JP2014540611A JP2014540611A JP2014534233A5 JP 2014534233 A5 JP2014534233 A5 JP 2014534233A5 JP 2014540611 A JP2014540611 A JP 2014540611A JP 2014540611 A JP2014540611 A JP 2014540611A JP 2014534233 A5 JP2014534233 A5 JP 2014534233A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- sequence
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 21
- 102000036639 antigens Human genes 0.000 claims 21
- 108091007433 antigens Proteins 0.000 claims 21
- 239000012634 fragment Substances 0.000 claims 21
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 17
- 150000001413 amino acids Chemical group 0.000 claims 16
- 235000001014 amino acid Nutrition 0.000 claims 13
- 208000007934 ACTH-independent macronodular adrenal hyperplasia Diseases 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 238000006467 substitution reaction Methods 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 239000004472 Lysine Substances 0.000 claims 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 5
- 239000002254 cytotoxic agent Substances 0.000 claims 5
- 229940127089 cytotoxic agent Drugs 0.000 claims 5
- 231100000599 cytotoxic agent Toxicity 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- BLUGYPPOFIHFJS-UUFHNPECSA-N (2s)-n-[(2s)-1-[[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical group CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 3
- 125000002252 acyl group Chemical group 0.000 claims 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 3
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 2
- KAHJVVNKEWQPJI-JXJGXUGVSA-N (2S)-2-acetamido-6-aminohexanoic acid (2S)-2-amino-3-methylbutanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC(=O)N[C@@H](CCCCN)C(O)=O KAHJVVNKEWQPJI-JXJGXUGVSA-N 0.000 claims 1
- -1 1,3-thiazol-2-yl Chemical group 0.000 claims 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 102100027212 Tumor-associated calcium signal transducer 2 Human genes 0.000 claims 1
- 229920001222 biopolymer Polymers 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 235000013477 citrulline Nutrition 0.000 claims 1
- 229960002173 citrulline Drugs 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 201000005443 oral cavity cancer Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 230000005751 tumor progression Effects 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Images
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161559015P | 2011-11-11 | 2011-11-11 | |
| US61/559,015 | 2011-11-11 | ||
| US201261640641P | 2012-04-30 | 2012-04-30 | |
| US61/640,641 | 2012-04-30 | ||
| US201261717288P | 2012-10-23 | 2012-10-23 | |
| US61/717,288 | 2012-10-23 | ||
| PCT/IB2012/056234 WO2013068946A2 (en) | 2011-11-11 | 2012-11-07 | Antibodies specific for trop-2 and their uses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015240754A Division JP6157575B2 (ja) | 2011-11-11 | 2015-12-10 | Ｔｒｏｐ−２に対して特異的な抗体およびこれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014534233A JP2014534233A (ja) | 2014-12-18 |
| JP2014534233A5 true JP2014534233A5 (cg-RX-API-DMAC7.html) | 2015-02-05 |
| JP5936702B2 JP5936702B2 (ja) | 2016-06-22 |
Family
ID=47216378
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014540611A Expired - Fee Related JP5936702B2 (ja) | 2011-11-11 | 2012-11-07 | Ｔｒｏｐ−２に対して特異的な抗体およびこれらの使用 |
| JP2015240754A Expired - Fee Related JP6157575B2 (ja) | 2011-11-11 | 2015-12-10 | Ｔｒｏｐ−２に対して特異的な抗体およびこれらの使用 |
| JP2017049125A Expired - Fee Related JP6475277B2 (ja) | 2011-11-11 | 2017-03-14 | Ｔｒｏｐ−２に対して特異的な抗体およびこれらの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015240754A Expired - Fee Related JP6157575B2 (ja) | 2011-11-11 | 2015-12-10 | Ｔｒｏｐ−２に対して特異的な抗体およびこれらの使用 |
| JP2017049125A Expired - Fee Related JP6475277B2 (ja) | 2011-11-11 | 2017-03-14 | Ｔｒｏｐ−２に対して特異的な抗体およびこれらの使用 |
Country Status (20)
Families Citing this family (154)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7585491B2 (en) | 2002-12-13 | 2009-09-08 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| US8435529B2 (en) | 2002-06-14 | 2013-05-07 | Immunomedics, Inc. | Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy |
| US9770517B2 (en) * | 2002-03-01 | 2017-09-26 | Immunomedics, Inc. | Anti-Trop-2 antibody-drug conjugates and uses thereof |
| WO2003074566A2 (en) | 2002-03-01 | 2003-09-12 | Immunomedics, Inc. | Rs7 antibodies |
| US9745380B2 (en) | 2002-03-01 | 2017-08-29 | Immunomedics, Inc. | RS7 antibodies |
| US9707302B2 (en) | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| US10058621B2 (en) | 2015-06-25 | 2018-08-28 | Immunomedics, Inc. | Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers |
| EP2635310A2 (en) * | 2010-11-05 | 2013-09-11 | Rinat Neuroscience Corp. | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| PT2663579T (pt) | 2011-01-14 | 2017-07-28 | Univ California | Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização |
| KR20140091040A (ko) * | 2011-11-11 | 2014-07-18 | 리나트 뉴로사이언스 코프. | Trop-2에 특이적인 항체 및 그의 용도 |
| US9717803B2 (en) | 2011-12-23 | 2017-08-01 | Innate Pharma | Enzymatic conjugation of polypeptides |
| US10132799B2 (en) | 2012-07-13 | 2018-11-20 | Innate Pharma | Screening of conjugated antibodies |
| WO2014057687A1 (ja) | 2012-10-11 | 2014-04-17 | 第一三共株式会社 | 抗体－薬物コンジュゲート |
| CA2890569C (en) | 2012-11-05 | 2019-03-05 | Pfizer Inc. | Spliceostatin analogs |
| EP3564259A3 (en) | 2012-11-09 | 2020-02-12 | Innate Pharma | Recognition tags for tgase-mediated conjugation |
| US10206918B2 (en) | 2012-12-13 | 2019-02-19 | Immunomedics, Inc. | Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers |
| CN104837508A (zh) | 2012-12-13 | 2015-08-12 | 免疫医疗公司 | 功效改进且毒性降低的抗体与sn-38的免疫缀合物的剂量 |
| US9492566B2 (en) | 2012-12-13 | 2016-11-15 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
| US12310958B2 (en) | 2012-12-13 | 2025-05-27 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
| US10137196B2 (en) | 2012-12-13 | 2018-11-27 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
| US20240148873A1 (en) | 2012-12-13 | 2024-05-09 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity |
| WO2014140300A1 (en) | 2013-03-15 | 2014-09-18 | Innate Pharma | Solid phase tgase-mediated conjugation of antibodies |
| KR20160018579A (ko) * | 2013-06-04 | 2016-02-17 | 싸이톰스 테라퓨틱스, 인크. | 활성화가능 항체를 접합하기 위한 조성물 및 방법 |
| WO2014202773A1 (en) | 2013-06-20 | 2014-12-24 | Innate Pharma | Enzymatic conjugation of polypeptides |
| CN105517577A (zh) * | 2013-06-21 | 2016-04-20 | 先天制药公司 | 多肽的酶促偶联 |
| US11253606B2 (en) | 2013-07-23 | 2022-02-22 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| WO2015015448A2 (en) * | 2013-07-31 | 2015-02-05 | Rinat Neuroscience Corp. | Engineered polypeptide conjugates |
| SI3424955T1 (sl) | 2013-12-25 | 2025-08-29 | Daiichi Sankyo Company, Limited | Metoda za proizvodnjo konjugata protitelo-zdravilo anti-trop2 |
| CN106662577B (zh) | 2014-01-24 | 2020-07-21 | 恩格姆生物制药公司 | 结合蛋白及其使用方法 |
| MY180257A (en) | 2014-01-27 | 2020-11-26 | Pfizer | Bifunctional cytotoxic agents |
| SI3101032T1 (sl) | 2014-01-31 | 2019-02-28 | Daiichi Sankyo Company, Limited | Konjugat zdravila s protitelesci ANTI-HER2 |
| ES2978993T3 (es) | 2014-02-21 | 2024-09-23 | Ibc Pharmaceuticals Inc | Terapia de enfermedades mediante la inducción de la respuesta inmunitaria a las células que expresan Trop-2 |
| EP3134127B1 (en) | 2014-04-25 | 2020-02-26 | Rinat Neuroscience Corp. | Antibody-drug conjugates with high drug loading |
| MX375284B (es) * | 2014-04-30 | 2025-03-06 | Pfizer | Conjugados de anticuerpo-fármaco anti-proteína tirosina quinasa 7 (anti-ptk7). |
| KR102451080B1 (ko) | 2014-06-12 | 2022-10-06 | 씨에스피씨 메가리스 바이오파마슈티칼 씨오., 엘티디. | 효소적 방법을 통한 균일한 항체 약물 접합체 |
| PL3185908T3 (pl) | 2014-08-28 | 2020-09-07 | Pfizer Inc. | Łączniki modulujące stabilność do stosowania z koniugatami przeciwciało-lek |
| EP3227340B1 (en) | 2014-12-04 | 2020-06-17 | Mediterranea Theranostic S.R.L. | Humanized anti-trop-2 monoclonal antibodies and uses thereof |
| CA2923862C (en) | 2015-03-20 | 2024-02-13 | Pfizer Inc. | Bifunctional cytotoxic agents containing the cti pharmacophore |
| CA2981543A1 (en) | 2015-04-22 | 2016-10-27 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells |
| US10195175B2 (en) | 2015-06-25 | 2019-02-05 | Immunomedics, Inc. | Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors |
| US11173213B2 (en) | 2015-06-29 | 2021-11-16 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| WO2015151081A2 (en) | 2015-07-12 | 2015-10-08 | Suzhou M-Conj Biotech Co., Ltd | Bridge linkers for conjugation of a cell-binding molecule |
| US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
| US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
| CN106554420A (zh) * | 2015-09-30 | 2017-04-05 | 上海众合医药科技股份有限公司 | Pcsk9抗体、其抗原结合片段及其医药用途 |
| US10689458B2 (en) | 2015-11-30 | 2020-06-23 | Pfizer Inc. | Site specific HER2 antibody drug conjugates |
| TWI703160B (zh) * | 2015-11-30 | 2020-09-01 | 美商輝瑞股份有限公司 | 用於部位專一性接合之抗體和抗體片段 |
| CN108601841A (zh) | 2016-02-10 | 2018-09-28 | 免疫医疗公司 | Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性 |
| WO2017147542A2 (en) | 2016-02-26 | 2017-08-31 | Regeneron Pharmaceuticals, Inc. | Optimized transglutaminase site-specific antibody conjugation |
| CN109843327B (zh) | 2016-07-07 | 2022-05-13 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
| CA3032559C (en) | 2016-08-03 | 2022-04-19 | Pfizer Inc. | Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates |
| WO2018036438A1 (zh) * | 2016-08-23 | 2018-03-01 | 四川科伦博泰生物医药股份有限公司 | 一种抗体-药物偶联物及其制备方法和应用 |
| WO2018086139A1 (en) | 2016-11-14 | 2018-05-17 | Hangzhou Dac Biotech Co., Ltd | Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers |
| EP3552626A4 (en) | 2016-12-12 | 2020-06-10 | Daiichi Sankyo Company, Limited | ASSOCIATION OF AN ANTIBODY DRUG CONJUGATE AND AN IMMUNE CONTROL POINT INHIBITOR |
| CN110382535A (zh) | 2017-01-17 | 2019-10-25 | 第一三共株式会社 | 抗-gpr20抗体以及抗-gpr20抗体-药物缀合物 |
| BR112019015069A2 (pt) | 2017-01-24 | 2020-03-03 | Pfizer Inc. | Derivados de caliqueamicina e conjugados de anticorpo-fármaco dos mesmos |
| CA3050332A1 (en) | 2017-03-27 | 2018-10-04 | Immunomedics, Inc. | Treatment of trop-2 expressing triple negative breast cancer with sacituzumab govitecan and a rad51 inhibitor |
| BR112019021520A2 (pt) | 2017-04-14 | 2020-08-04 | Tollnine, Inc. | oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune |
| CN110914289B (zh) | 2017-05-12 | 2024-05-14 | 克里斯珀医疗股份公司 | 用于工程化细胞的材料和方法及其在免疫肿瘤学中的用途 |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| TW202530219A (zh) | 2017-05-15 | 2025-08-01 | 日商第一三共股份有限公司 | 抗體－藥物結合物之製造方法 |
| WO2018213335A1 (en) | 2017-05-16 | 2018-11-22 | Scalmibio, Inc. | Activatable antibodies and methods of use thereof |
| CN107446050A (zh) * | 2017-08-11 | 2017-12-08 | 百奥泰生物科技(广州)有限公司 | Trop2阳性疾病治疗的化合物及方法 |
| WO2019044946A1 (ja) | 2017-08-31 | 2019-03-07 | 第一三共株式会社 | 抗体－薬物コンジュゲートの新規製造方法 |
| JP7366745B2 (ja) | 2017-08-31 | 2023-10-23 | 第一三共株式会社 | 抗体－薬物コンジュゲートの改良製造方法 |
| PE20210666A1 (es) | 2018-05-11 | 2021-03-31 | Crispr Therapeutics Ag | Metodos y composiciones para tratar el cancer |
| US12479926B2 (en) | 2018-05-18 | 2025-11-25 | Daiichi Sankyo Co., Ltd. | Anti-MUC1 antibody-drug conjugate |
| CN114014932A (zh) * | 2018-07-09 | 2022-02-08 | 启德医药科技（苏州）有限公司 | 滋养层细胞表面抗原2(trop2)特异性抗体 |
| TWI846717B (zh) | 2018-07-27 | 2024-07-01 | 日商第一三共股份有限公司 | 辨識抗體-藥物結合物之藥物部位的蛋白質 |
| CN112805036A (zh) | 2018-07-31 | 2021-05-14 | 第一三共株式会社 | 通过施用抗体-药物缀合物对转移性脑肿瘤的治疗 |
| US12312641B2 (en) | 2018-08-23 | 2025-05-27 | Daiichi Sankyo Company, Limited | Sensitivity marker for antibody-drug conjugate |
| CN112888445B (zh) | 2018-08-30 | 2025-06-10 | 免疫生物公司 | 治疗老年化相关病症的方法 |
| JP7407822B2 (ja) | 2018-08-30 | 2024-01-04 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 単鎖キメラポリペプチドおよびその使用 |
| EP4659757A2 (en) | 2018-08-30 | 2025-12-10 | ImmunityBio, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| CN113260384A (zh) | 2018-11-05 | 2021-08-13 | 西纳福克斯股份有限公司 | 用于靶向表达trop-2的肿瘤的抗体缀合物 |
| AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| US12458818B2 (en) | 2019-03-19 | 2025-11-04 | CSPC Megalith Biopharmaceutical Co., Ltd. | Anti-trophoblast cell surface antigen 2 (TROP2) antibodies and antibody drug conjugates comprising same |
| EA202192975A1 (ru) | 2019-04-30 | 2022-02-01 | Криспр Терапьютикс Аг | Аллогенная клеточная терапия b-клеточных злокачественных новообразований с применением генетически сконструированных т-клеток, нацеливающихся на cd19 |
| WO2020228604A1 (zh) * | 2019-05-10 | 2020-11-19 | 江苏豪森药业集团有限公司 | 抗trop-2抗体、其抗原结合片段及其医药用途 |
| WO2020240467A1 (en) | 2019-05-29 | 2020-12-03 | Daiichi Sankyo Company, Limited | Dosage of an antibody-drug conjugate |
| WO2020257639A1 (en) | 2019-06-21 | 2020-12-24 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| KR20220029725A (ko) | 2019-06-29 | 2022-03-08 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 세포-결합 분자-튜불리신 유도체 접합체 및 이의 제조 방법 |
| CN112390885B (zh) * | 2019-08-12 | 2024-01-19 | 凯惠科技发展(上海)有限公司 | 一种trop2抗体及其制备方法、其偶联物和应用 |
| CN112646038B (zh) * | 2019-10-11 | 2025-06-03 | 迈威(上海)生物科技股份有限公司 | 抗人Trop-2抗体及其应用 |
| WO2021136483A1 (en) * | 2019-12-31 | 2021-07-08 | Genequantum Healthcare (Suzhou) Co., Ltd. | Anti-trop2 antibodies, antibody-drug conjugates, and application of the same |
| CN115362169A (zh) | 2020-02-11 | 2022-11-18 | Hcw生物科技公司 | 色谱树脂以及其用途 |
| WO2021163369A2 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of treating age-related and inflammatory diseases |
| JP2023519107A (ja) | 2020-02-11 | 2023-05-10 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 制御性ｔ細胞を活性化する方法 |
| US20210316003A1 (en) | 2020-03-20 | 2021-10-14 | Immunomedics, Inc. | Biomarkers for sacituzumab govitecan therapy |
| CN113527498B (zh) * | 2020-04-16 | 2022-03-04 | 上海洛启生物医药技术有限公司 | 抗Trop2纳米抗体及其应用 |
| JP7734693B2 (ja) | 2020-04-29 | 2025-09-05 | イミュニティーバイオ インコーポレイテッド | 抗ｃｄ２６タンパク質及びそれらの使用法 |
| CN115996756A (zh) | 2020-05-08 | 2023-04-21 | 博尔特生物治疗药物有限公司 | 弹性蛋白酶底物肽连接子免疫缀合物及其用途 |
| JP2023527869A (ja) | 2020-06-01 | 2023-06-30 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 加齢関連障害の治療法 |
| US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| WO2021247908A1 (en) * | 2020-06-03 | 2021-12-09 | Bionecure Therapeutics, Inc. | Trophoblast cell-surface antigen-2 (trop-2) antibodies |
| WO2021259162A1 (zh) * | 2020-06-22 | 2021-12-30 | 四川百利药业有限责任公司 | 一种抗trop2抗体 |
| CA3186059A1 (en) | 2020-08-13 | 2022-02-17 | Romas Kudirka | Pyrazoloazepine immunoconjugates, and uses thereof |
| TWI889920B (zh) * | 2020-10-14 | 2025-07-11 | 大陸商上海翰森生物醫藥科技有限公司 | 抗ｔｒｏｐ-２抗體、其抗原結合片段或其突變體、及其醫藥用途 |
| CN112321715B (zh) * | 2020-11-03 | 2022-05-10 | 博奥信生物技术（南京）有限公司 | 抗trop2纳米抗体及其制备方法和应用 |
| IT202000031838A1 (it) * | 2020-12-22 | 2022-06-22 | Saverio Alberti | Piattaforma per ottenere anticorpi monoclonali diretti contro antigeni processati tumore-specifici |
| CN114685669A (zh) * | 2020-12-30 | 2022-07-01 | 和铂医药(苏州)有限公司 | 结合trop2的抗体及其用途 |
| US20240197899A1 (en) | 2021-03-26 | 2024-06-20 | Bolt Biotherapeutics, Inc. | 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof |
| US20240299569A1 (en) | 2021-03-26 | 2024-09-12 | Bolt Biotherapeutics, Inc. | 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof |
| US20240269315A1 (en) | 2021-06-02 | 2024-08-15 | Bio-Thera Solutions, Ltd. | Drug conjugate and use thereof |
| US11957693B2 (en) | 2021-06-11 | 2024-04-16 | Gilead Sciences, Inc. | Combination MCL-1 inhibitors with anti-cancer agents |
| EP4351657A1 (en) | 2021-06-11 | 2024-04-17 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-body drug conjugates |
| EP4355785A1 (en) | 2021-06-17 | 2024-04-24 | Amberstone Biosciences, Inc. | Anti-cd3 constructs and uses thereof |
| CN115536747B (zh) * | 2021-06-30 | 2024-08-27 | 益科思特(北京)医药科技发展有限公司 | 一种结合trop2的抗体及靶向trop2和cd3的双特异性抗体及其制备方法与应用 |
| CN115558026A (zh) * | 2021-07-02 | 2023-01-03 | 和迈生物科技有限公司 | 抗trop2单域抗体及其应用 |
| CN118139891A (zh) * | 2021-09-23 | 2024-06-04 | 上海翰森生物医药科技有限公司 | 抗体药物偶联物及其制备方法和医药用途 |
| EP4408468A4 (en) * | 2021-09-28 | 2025-07-02 | Frontaim Biomedicines Inc | MULTIPLE FORMATS OF MOLECULAR COMPLEXES |
| AU2022375782A1 (en) | 2021-10-28 | 2024-05-02 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| JP2024539993A (ja) | 2021-10-29 | 2024-10-31 | ボルト バイオセラピューティクス、インコーポレーテッド | システイン変異抗体を含むｔｌｒアゴニスト免疫複合体、及びその使用 |
| US11919869B2 (en) | 2021-10-29 | 2024-03-05 | Gilead Sciences, Inc. | CD73 compounds |
| JP2024541058A (ja) | 2021-11-03 | 2024-11-06 | ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． | 抗体の特異的共役 |
| AU2022401024A1 (en) | 2021-11-30 | 2024-05-16 | Daiichi Sankyo Company, Limited | Protease-cleavable masked antibodies |
| CN120795159A (zh) * | 2021-12-02 | 2025-10-17 | 浙江博锐生物制药有限公司 | 抗Trop-2抗体及其用途 |
| EP4438627A1 (en) * | 2021-12-07 | 2024-10-02 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Anti-trop-2 antibody or antigen-binding fragment thereof |
| CA3237577A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CN118488946A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| EP4477674A1 (en) | 2022-02-09 | 2024-12-18 | Daiichi Sankyo Company, Limited | Environmentally responsive masked antibody and use thereof |
| EP4479042A1 (en) | 2022-02-18 | 2024-12-25 | Massachusetts Institute Of Technology | Cancer treatment by combined inhibition of polo-like kinase and microtubule polymerization |
| JP2025508939A (ja) | 2022-03-02 | 2025-04-10 | イミュニティーバイオ インコーポレイテッド | 膵臓癌の治療方法 |
| ES2999273T3 (en) | 2022-03-17 | 2025-02-25 | Gilead Sciences Inc | Ikaros zinc finger family degraders and uses thereof |
| KR20250024743A (ko) | 2022-03-23 | 2025-02-19 | 시나픽스 비.브이. | Trop-2를 발현하는 종양을 표적화하기 위한 항체-컨쥬게이트 |
| WO2023201267A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| WO2023201268A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating tumor antigen expressing cancers |
| KR20250004824A (ko) | 2022-04-21 | 2025-01-08 | 길리애드 사이언시즈, 인코포레이티드 | Kras g12d 조절 화합물 |
| WO2024002042A1 (zh) | 2022-06-27 | 2024-01-04 | 百奥泰生物制药股份有限公司 | 治疗实体瘤的方法 |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| CN117430710B (zh) * | 2022-07-21 | 2025-07-04 | 中国医学科学院医药生物技术研究所 | 一种针对Trop2的单克隆抗体及其应用 |
| WO2024097812A1 (en) | 2022-11-04 | 2024-05-10 | Gilead Sciences, Inc. | Therapy for treating bladder cancer |
| AU2023409398A1 (en) | 2022-12-22 | 2025-06-05 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| TW202432187A (zh) | 2022-12-23 | 2024-08-16 | 美商建南德克公司 | 小腦蛋白降解劑結合物及其用途 |
| AU2024210908A1 (en) | 2023-01-18 | 2025-08-21 | Tyligand Bioscience (Shanghai) Limited | Antibody-drug conjugate and use thereof |
| EP4665404A1 (en) | 2023-02-14 | 2025-12-24 | Bolt Biotherapeutics, Inc. | Aza-benzazepine immunoconjugates, and uses thereof |
| WO2024186626A1 (en) | 2023-03-03 | 2024-09-12 | Bolt Biotherapeutics, Inc. | Aza-bicyclic sting agonist immunoconjugates, and uses thereof |
| WO2024215754A1 (en) | 2023-04-11 | 2024-10-17 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2024226410A1 (en) | 2023-04-24 | 2024-10-31 | Merck Sharp & Dohme Llc | Trop2 binders and conjugates thereof |
| WO2025006720A1 (en) | 2023-06-30 | 2025-01-02 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2025010028A1 (en) * | 2023-07-05 | 2025-01-09 | Agency For Science, Technology And Research | Anti-trop2 antibodies |
| WO2025019790A1 (en) | 2023-07-19 | 2025-01-23 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc |
| US20250100998A1 (en) | 2023-07-26 | 2025-03-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025024663A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025111445A1 (en) * | 2023-11-21 | 2025-05-30 | Convergent Therapeutics, Inc. | Trop-2 radiopharmaceutical conjugate and uses thereof |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| US20250376484A1 (en) | 2024-05-21 | 2025-12-11 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025250825A1 (en) * | 2024-05-30 | 2025-12-04 | Sutro Biopharma, Inc. | Anti-trop2 antibodies, compositions comprising anti-trop2 antibodies and methods of making and using anti-trop2 antibodies |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1990007936A1 (en) | 1989-01-23 | 1990-07-26 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
| ES2200016T3 (es) | 1989-03-21 | 2004-03-01 | Vical Incorporated | Expresion de secuencias polinucleotidicas exogenas en un vertebrado. |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
| AU641673B2 (en) | 1989-06-29 | 1993-09-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| WO1991002805A2 (en) | 1989-08-18 | 1991-03-07 | Viagene, Inc. | Recombinant retroviruses delivering vector constructs to target cells |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| NZ237464A (en) | 1990-03-21 | 1995-02-24 | Depotech Corp | Liposomes with at least two separate chambers encapsulating two separate biologically active substances |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
| US5278299A (en) | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
| CA2102511A1 (en) | 1991-05-14 | 1992-11-15 | Paul J. Higgins | Heteroconjugate antibodies for treatment of hiv infection |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| ES2197145T3 (es) | 1991-08-20 | 2004-01-01 | The Government Of The Usa As Represented By The Secretary Of The Deptm. Of Health And Human Services | Transferencia de genes mediada por adenovirus al gastrointestinal. |
| CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| ATE181571T1 (de) | 1991-09-23 | 1999-07-15 | Medical Res Council | Methoden zur herstellung humanisierter antikörper |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| WO1993010260A1 (en) | 1991-11-21 | 1993-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| WO1993025234A1 (en) | 1992-06-08 | 1993-12-23 | The Regents Of The University Of California | Methods and compositions for targeting specific tissue |
| JPH09507741A (ja) | 1992-06-10 | 1997-08-12 | アメリカ合衆国 | ヒト血清による不活性化に耐性のあるベクター粒子 |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| CA2140280A1 (en) | 1992-08-17 | 1994-03-03 | Avi J. Ashkenazi | Bispecific immunoadhesins |
| WO1994009817A1 (en) | 1992-11-04 | 1994-05-11 | City Of Hope | Novel antibody construct |
| US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
| JPH08503855A (ja) | 1992-12-03 | 1996-04-30 | ジェンザイム・コーポレイション | 嚢胞性線維症に対する遺伝子治療 |
| US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| EP0695169B1 (en) | 1993-04-22 | 2002-11-20 | SkyePharma Inc. | Multivesicular cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| AU687829B2 (en) | 1993-06-24 | 1998-03-05 | Advec, Inc. | Adenovirus vectors for gene therapy |
| DE69433461T2 (de) | 1993-09-15 | 2004-11-18 | Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville | Rekombinanter Alphavirus Vektor |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| HU223733B1 (hu) | 1993-10-25 | 2004-12-28 | Canji, Inc. | Rekombináns adenovírus vektor és eljárás alkalmazására |
| KR100241300B1 (ko) | 1993-11-16 | 2000-03-02 | Sheldon A. Schaffer | 활성물질의 조절된 방출성을 갖는 소포 |
| US6436908B1 (en) | 1995-05-30 | 2002-08-20 | Duke University | Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function |
| CA2158977A1 (en) | 1994-05-09 | 1995-11-10 | James G. Respess | Retroviral vectors having a reduced recombination rate |
| WO1996017072A2 (en) | 1994-11-30 | 1996-06-06 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| ATE265532T1 (de) | 1995-10-19 | 2004-05-15 | Bristol Myers Squibb Co | Monoklonaler antikörper br110 und dessen anwendung |
| AU2998597A (en) | 1996-05-06 | 1997-11-26 | Chiron Corporation | Crossless retroviral vectors |
| US6653104B2 (en) | 1996-10-17 | 2003-11-25 | Immunomedics, Inc. | Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells |
| US5850854A (en) | 1997-10-02 | 1998-12-22 | Carroll; Norman Lee | Pipe closure |
| US6376471B1 (en) | 1997-10-10 | 2002-04-23 | Johns Hopkins University | Gene delivery compositions and methods |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| WO2000009560A2 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| JP2003527561A (ja) * | 1999-01-22 | 2003-09-16 | スミスクライン・ビーチャム・コーポレイション | 蛋白の部位特異的標識化方法およびそのための使用 |
| WO2000053211A2 (en) | 1999-03-09 | 2000-09-14 | University Of Southern California | Method of promoting myocyte proliferation and myocardial tissue repair |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| CA2427858A1 (en) * | 2000-11-03 | 2002-05-10 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
| WO2003074566A2 (en) | 2002-03-01 | 2003-09-12 | Immunomedics, Inc. | Rs7 antibodies |
| US9745380B2 (en) | 2002-03-01 | 2017-08-29 | Immunomedics, Inc. | RS7 antibodies |
| SI2263692T1 (sl) | 2002-12-24 | 2020-10-30 | Rinat Neuroscience Corp. | Anti-NGF protitelesa in postopki, v katerih se le-ta uporabljajo |
| US20080025977A1 (en) | 2003-04-14 | 2008-01-31 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD59 |
| EP1871417B1 (en) | 2005-04-15 | 2013-09-11 | Precision Biologics, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| US20080213267A1 (en) | 2006-02-24 | 2008-09-04 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| US7420040B2 (en) * | 2006-02-24 | 2008-09-02 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| US20080131428A1 (en) * | 2006-02-24 | 2008-06-05 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| WO2008101957A1 (en) * | 2007-02-22 | 2008-08-28 | Novo Nordisk Health Care Ag | Modulating enzymatic processes by addition of diolcontaining substances |
| JP6022444B2 (ja) | 2010-05-14 | 2016-11-09 | ライナット ニューロサイエンス コーポレイション | ヘテロ二量体タンパク質ならびにそれを生産および精製するための方法 |
| JPWO2011155579A1 (ja) | 2010-06-10 | 2013-08-15 | 北海道公立大学法人 札幌医科大学 | 抗Ｔｒｏｐ−２抗体 |
| EP2635310A2 (en) | 2010-11-05 | 2013-09-11 | Rinat Neuroscience Corp. | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| KR20140091040A (ko) * | 2011-11-11 | 2014-07-18 | 리나트 뉴로사이언스 코프. | Trop-2에 특이적인 항체 및 그의 용도 |
| EP2780039B9 (en) | 2011-11-17 | 2018-04-18 | Pfizer Inc | Cytotoxic peptides and antibody drug conjugates thereof |
-
2012
- 2012-11-07 KR KR1020147015364A patent/KR20140091040A/ko not_active Ceased
- 2012-11-07 AR ARP120104194A patent/AR088693A1/es unknown
- 2012-11-07 RU RU2014116406/10A patent/RU2014116406A/ru not_active Application Discontinuation
- 2012-11-07 CN CN201280055208.2A patent/CN104053672A/zh active Pending
- 2012-11-07 US US13/670,730 patent/US8871908B2/en not_active Expired - Fee Related
- 2012-11-07 CA CA2854720A patent/CA2854720C/en not_active Expired - Fee Related
- 2012-11-07 PH PH1/2014/500932A patent/PH12014500932A1/en unknown
- 2012-11-07 HK HK15102314.8A patent/HK1201851A1/xx unknown
- 2012-11-07 SG SG11201401699WA patent/SG11201401699WA/en unknown
- 2012-11-07 EP EP12788646.3A patent/EP2776470A2/en not_active Ceased
- 2012-11-07 CA CA2954166A patent/CA2954166A1/en not_active Abandoned
- 2012-11-07 WO PCT/IB2012/056234 patent/WO2013068946A2/en not_active Ceased
- 2012-11-07 MX MX2014005728A patent/MX2014005728A/es unknown
- 2012-11-07 AU AU2012335205A patent/AU2012335205A1/en not_active Abandoned
- 2012-11-07 BR BR112014011331A patent/BR112014011331A2/pt not_active IP Right Cessation
- 2012-11-07 TW TW101141373A patent/TWI495644B/zh not_active IP Right Cessation
- 2012-11-07 JP JP2014540611A patent/JP5936702B2/ja not_active Expired - Fee Related
- 2012-11-07 SA SA112330988A patent/SA112330988B1/ar unknown
-
2014
- 2014-05-01 IL IL232426A patent/IL232426A0/en unknown
- 2014-05-09 CO CO14100190A patent/CO7010785A2/es unknown
- 2014-05-14 ZA ZA2014/03492A patent/ZA201403492B/en unknown
- 2014-08-15 US US14/460,871 patent/US9399074B2/en not_active Expired - Fee Related
-
2015
- 2015-12-10 JP JP2015240754A patent/JP6157575B2/ja not_active Expired - Fee Related
-
2016
- 2016-05-20 US US15/160,742 patent/US10100114B2/en not_active Expired - Fee Related
-
2017
- 2017-03-14 JP JP2017049125A patent/JP6475277B2/ja not_active Expired - Fee Related
-
2018
- 2018-09-07 US US16/125,032 patent/US11091544B2/en not_active Expired - Fee Related